Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus PROCTOFOAM HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus PROCTOFOAM HC.
CAPEX vs PROCTOFOAM HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Hydrocortisone is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by binding to cytoplasmic glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression, leading to suppression of inflammatory mediators (e.g., prostaglandins, leukotrienes) and inhibition of immune cell migration. Pramoxine is a local anesthetic that reversibly blocks sodium ion channels in nerve membranes, thereby inhibiting initiation and conduction of sensory nerve impulses.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Rectal aerosol foam: 1 applicatorful (6.5% pramoxine HCl / 1% hydrocortisone) rectally 2-3 times daily. Maximum 4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
The terminal elimination half-life of hydrocortisone is approximately 1.5-2 hours. After topical application to the rectal mucosa, systemic absorption is minimal, resulting in a half-life comparable to that of endogenous cortisol, with clinical effects lasting about 6-8 hours.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Hydrocortisone is metabolized in the liver, primarily to inactive metabolites (tetrahydrocortisone and tetrahydrocortisol). Less than 1% of the dose is excreted unchanged in urine. Fecal excretion is negligible.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid